Molecular Partners AG

BATS-CHIXE:MOLNZ Stock Report

Market Cap: CHF 162.4m

Molecular Partners Valuation

Is MOLNZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MOLNZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MOLNZ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MOLNZ's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MOLNZ?

Key metric: As MOLNZ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MOLNZ. This is calculated by dividing MOLNZ's market cap by their current revenue.
What is MOLNZ's PS Ratio?
PS Ratio27.1x
SalesCHF 6.00m
Market CapCHF 162.43m

Price to Sales Ratio vs Peers

How does MOLNZ's PS Ratio compare to its peers?

The above table shows the PS ratio for MOLNZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average11.2x
BVXP Bioventix
11.6xn/aUK£157.6m
OXB Oxford Biomedica
4.4x21.2%UK£423.4m
OPTI OptiBiotix Health
27.1xn/aUK£15.4m
TRX Tissue Regenix Group
1.6x15.1%UK£42.0m
MOLNZ Molecular Partners
27.1x50.9%CHF 162.4m

Price-To-Sales vs Peers: MOLNZ is expensive based on its Price-To-Sales Ratio (27.1x) compared to the peer average (11.2x).

Price to Sales Ratio vs Industry

How does MOLNZ's PS Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
1.8x3.5%US$1.46b
TRX Tissue Regenix Group
1.6x15.1%US$52.15m
VRCI Verici Dx
2.6x78.8%US$11.29m
0HMP Bellerophon Therapeutics
0.09xn/aUS$489.31k
No more companies available in this PS range
No. of Companies5PS01224364860+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: MOLNZ is expensive based on its Price-To-Sales Ratio (27.1x) compared to the European Biotechs industry average (8.3x).

Price to Sales Ratio vs Fair Ratio

What is MOLNZ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MOLNZ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio27.1x
Fair PS Ratio0.009x

Price-To-Sales vs Fair Ratio: MOLNZ is expensive based on its Price-To-Sales Ratio (27.1x) compared to the estimated Fair Price-To-Sales Ratio (0x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MOLNZ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 4.45
CHF 9.75
+119.2%
53.8%CHF 15.00CHF 4.50n/a2
Feb ’26CHF 4.78
CHF 9.75
+104.1%
53.8%CHF 15.00CHF 4.50n/a2
Jan ’26CHF 4.14
CHF 9.75
+135.5%
53.8%CHF 15.00CHF 4.50n/a2
Dec ’25CHF 5.25
CHF 9.75
+85.7%
53.8%CHF 15.00CHF 4.50n/a2
Nov ’25CHF 5.33
CHF 9.75
+82.9%
53.8%CHF 15.00CHF 4.50n/a2
Oct ’25CHF 4.08
CHF 9.75
+139.3%
53.8%CHF 15.00CHF 4.50n/a2
Sep ’25CHF 5.15
CHF 9.75
+89.3%
53.8%CHF 15.00CHF 4.50n/a2
Aug ’25CHF 5.95
CHF 9.35
+57.1%
60.4%CHF 15.00CHF 3.70n/a2
Jul ’25CHF 6.63
CHF 9.35
+41.1%
60.4%CHF 15.00CHF 3.70n/a2
Jun ’25CHF 3.40
CHF 9.35
+175.0%
60.4%CHF 15.00CHF 3.70n/a2
May ’25CHF 3.27
CHF 9.35
+185.7%
60.4%CHF 15.00CHF 3.70n/a2
Apr ’25CHF 3.64
CHF 9.50
+161.3%
57.9%CHF 15.00CHF 4.00n/a2
Mar ’25CHF 3.82
CHF 9.50
+148.7%
57.9%CHF 15.00CHF 4.00n/a2
Feb ’25CHF 3.98
CHF 9.50
+139.0%
57.9%CHF 15.00CHF 4.00CHF 4.782
Jan ’25CHF 3.55
CHF 9.50
+168.0%
57.9%CHF 15.00CHF 4.00CHF 4.142
Dec ’24CHF 3.86
CHF 10.50
+172.0%
42.9%CHF 15.00CHF 6.00CHF 5.252
Nov ’24CHF 3.15
CHF 10.50
+233.3%
42.9%CHF 15.00CHF 6.00CHF 5.332
Oct ’24CHF 3.75
CHF 10.50
+180.4%
42.9%CHF 15.00CHF 6.00CHF 4.082
Sep ’24CHF 5.20
CHF 9.00
+73.1%
47.1%CHF 15.00CHF 6.00CHF 5.153
Aug ’24CHF 5.50
CHF 9.00
+63.6%
47.1%CHF 15.00CHF 6.00CHF 5.953
Jul ’24CHF 5.49
CHF 9.00
+63.9%
47.1%CHF 15.00CHF 6.00CHF 6.633
Jun ’24CHF 5.67
CHF 14.00
+146.9%
80.8%CHF 30.00CHF 6.00CHF 3.403
May ’24CHF 5.95
CHF 13.00
+118.5%
76.5%CHF 30.00CHF 6.00CHF 3.274
Apr ’24CHF 5.40
CHF 12.87
+138.3%
69.2%CHF 30.00CHF 6.00CHF 3.645
Mar ’24CHF 5.91
CHF 12.87
+117.7%
69.2%CHF 30.00CHF 6.00CHF 3.825
Feb ’24CHF 5.86
CHF 12.87
+119.6%
69.2%CHF 30.00CHF 6.00CHF 3.985
Analyst Price Target
Consensus Narrative from 2 Analysts
CHF 9.84
Fair Value
54.8% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/09 19:37
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Molecular Partners AG is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jo WaltonCredit Suisse
null nullCredit Suisse
Thomas KaufmannCredit Suisse